Clinical Trial Update: Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Florbetapir F 18 PET imaging to inform clinical diagnosis and management in patients with progressive cognitive decline. Results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• Florbetapir F-18 (florbetapir F-18)

Snippet

Sponsor: Avid Radiopharmaceuticals | Conditions: Progressive Cognitive Decline | Phase 3 | Status: COMPLETED | Results posted: 2013-03-22